Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 17/20 | 0.66 |
| ▸ | DHFR | P00374 | 3/20 | 0.66 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.66 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.66 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 0.66 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.66 |
| ▸ | GART | P22102 | 1/20 | 0.66 |
| ▸ | ATIC | P31939 | 1/20 | 0.66 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.66 |
| ▸ | FRK | P42685 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12042271 | 1.00 | TYMS (0.66) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL12314789 | 0.91 | TYMS (0.66) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL13181213 | 0.90 | TYMS (0.78) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL18659339 | 0.90 | TYMS (0.78) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL2610602 | 0.90 | TYMS (0.67) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL14665910 | 0.89 | GART (0.81) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL14523040 | 0.87 | TYMS (0.63) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL13448780 | 0.86 | TYMS (0.67) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL10306802 | 0.85 | DHFR (0.54) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL12314803 | 0.84 | TYMS (0.60) | TYMSDHFRFOLR1SLC19A1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259348-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | SHILPA MEDICARE LIMITED (IN) | 2015-09-17 | — | — | US | disclosed |
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | Chelsea Thereapeutics, Inc. | 2011-06-23 | — | — | US | disclosed |
| US-7951812-B2 | For abnormal cell proliferation, inflammatory diseases, asthma, and arthritis; (S)-N-{4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-4-methylene-L-glutamic acid disodium salt (CHL1007) | CHELSEA THERAPEUTICS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7875716-B2 | Such as n-[4-[[2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]pseudoglutamic ester; synthesis; efficacy; reduced renal toxicity and other adverse side effects; cancer | STOICESCU DAN | 2011-01-25 | — | — | US | disclosed |
| US-7718660-B2 | Inhibitors of folic acid-dependent enzymes | STOICESCU DAN | 2010-05-18 | — | — | US | disclosed |
| US-20090247549-A1 | Methods of using saha and bortezomib for treating cancer | SCHERING CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090181990-A1 | STABLE AMORPHOUS FORM OF PEMETREXED DISODIUM | SUN PHARMA ADVANCE RESEARCH COMPANY (IN) | 2009-07-16 | — | — | US | disclosed |
| US-20080214550-A1 | Novel inhibitors of folic acid-dependent enzymes | STOICESCU DAN | 2008-09-04 | — | — | US | disclosed |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | CHELSEA THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080207652-A1 | Novel inhibitors of folic acid-dependent enzymes | STOICESCU DAN | 2008-08-28 | — | — | US | disclosed |
| WO-2008089390-A1 | NEW CLASSICAL ANTIFOLATES | CHELSEA THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247549-A1 | Methods of using saha and bortezomib for treating cancer | HDAC5, HDAC6, HDAC4 | TYMS 3819/4885DHFR 3294/4885FOLR1 4049/4885 |
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | CCR9, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNO | TYMS 154/4885DHFR 105/4885FOLR1 171/4885 |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | FFAR3, CCR9, NR1H3 | TYMS 1972/4885DHFR 517/4885FOLR1 271/4885 |
| US-20150259348-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | DPYD, KCNK5, KCNJ11 | TYMS 4/4885DHFR 62/4885FOLR1 235/4885 |
| US-20080207652-A1 | Novel inhibitors of folic acid-dependent enzymes | FOLR2, FOLR1, DHFR | TYMS 18/4885DHFR 3/4885FOLR1 2/4885 |
| US-20080214550-A1 | Novel inhibitors of folic acid-dependent enzymes | FOLR2, FOLR1, DHFR | TYMS 25/4885DHFR 3/4885FOLR1 2/4885 |
| US-20090181990-A1 | STABLE AMORPHOUS FORM OF PEMETREXED DISODIUM | TYMP, TYMS, MTHFD1 | TYMS 2/4885DHFR 22/4885FOLR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.